Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
MOMA Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
Atavistik Bio, Inc
Monte Rosa Therapeutics, Inc
Duke University
AstraZeneca
Sapience Therapeutics
Memorial Sloan Kettering Cancer Center
Loma Linda University
University of Maryland, Baltimore
Dana-Farber Cancer Institute
Medstar Health Research Institute
Memorial Sloan Kettering Cancer Center
Swiss Cancer Institute
Complement Theory Inc.
University of Southern California
NeoTX Therapeutics Ltd.
UNICANCER
National Cancer Institute (NCI)
Pfizer
Vanderbilt-Ingram Cancer Center
University of Colorado, Denver
Sensei Biotherapeutics, Inc.
University of Alabama at Birmingham
University College, London
OncoC4, Inc.
Memorial Sloan Kettering Cancer Center
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Theratechnologies
Carisma Therapeutics Inc
University of Toronto
Region Örebro County
NGM Biopharmaceuticals, Inc